Indeed, IFNα-2b (trade name Intron-A), a well-known IFN-based therapeutic (13) that is approved for the treatment of various infectious diseases as well as for many types of cancer including leukemia, lymphoma, multiple myeloma and malignant melanoma, is also actively used in multiple clinical trials (http://www.druglib.com/druginfo/intron-a/trials/). The gene discussed is IFNA2; the disease is cancer.